Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227961 · ClinicalTrials.gov registry record
PROMIS and Mobility Evaluation in Sarcoma Patients
A clinical trial of Sarcoma and Giant Cell Tumor of Bone, sponsored by University of Calgary.
- Recruiting
- Registry status
- 800
- Enrollment target
- 4
- Study locations
NCT07227961 is a study of Sarcoma and Giant Cell Tumor of Bone that is actively recruiting participants, run by University of Calgary. The registered enrollment target is 800 participants, below the 915-participant average among 122 other Sarcoma trials with a reported enrollment target (13% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT07227961, a study of Sarcoma and Giant Cell Tumor of Bone, is actively recruiting participants, sponsored by University of Calgary.
- RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this is to validate the Patient-Reported Outcomes Measurement Information System (PROMIS) in sarcoma patients undergoing surgery, and to evaluate a novel smartphone app for collecting mobility data. The goals of the study include to: 1. Validate PROMIS as a patient outcome measure in sarcoma 2. Assess the effectiveness of a novel app for administering questionnaires and collecting mobility metrics 3. Compare PROMIS scores and mobility metrics to better evaluate recovery trajectories after surgery Participants will complete PROMIS questionnaires at regularly scheduled intervals using the smartphone app. Questionnaires will be completed pre-operatively and at 6 weeks, 12 weeks, 6 months, and 12 months post-operatively. Additionally, the app will passively track mobility metrics such as daily step count, stairs climbed, and gait parameters to compare with PROMIS scores.
Conditions Studied
Interventions
- PROCEDURE Surgery
Study Locations (4)
Arizona
- Mayo Clinic - Phoenix
Minnesota
- Mayo Clinic - Rochester
Alberta
- Foothills Medical Centre, Arthur J Child Comprehensive Cancer Centre, University of Calgary - Calgary
Ontario
- Mount Sinai Hospital, University of Toronto - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2031-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07227961
The ClinicalTrials.gov registry entry for NCT07227961 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 915-participant average among 122 other Sarcoma trials with a reported enrollment target (13% lower). The listed sponsor is University of Calgary, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Surgery is the first listed.
NCT07227961 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Minnesota, Alberta.
Frequently Asked Questions
What is clinical trial NCT07227961 about?
NCT07227961 is a clinical study titled "PROMIS and Mobility Evaluation in Sarcoma Patients". The goal of this is to validate the Patient-Reported Outcomes Measurement Information System (PROMIS) in sarcoma patients undergoing surgery, and to evaluate a novel smartphone app for collecting mobility data. The goals of the study include to: 1. Validate PROMIS as a patient outcome measure in sa...
What is the current status of trial NCT07227961?
This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2025-07-01. Estimated completion is 2031-01-01.
What conditions does trial NCT07227961 study?
This clinical trial studies the following conditions: Sarcoma, Giant Cell Tumor of Bone.
What interventions are being tested in trial NCT07227961?
The interventions under investigation include: Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT07227961?
This trial is sponsored by University of Calgary, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07227961 being conducted?
This trial has 4 study locations across Arizona, Minnesota, Alberta, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
RECRUITING
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
RECRUITING
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Enhanced Recovery After Surgery in Extremity Sarcoma
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.